118 related articles for article (PubMed ID: 19404957)
1. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.
Damjanov N; Kauffman RS; Spencer-Green GT
Arthritis Rheum; 2009 May; 60(5):1232-41. PubMed ID: 19404957
[TBL] [Abstract][Full Text] [Related]
2. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Cohen S; Tuckwell K; Katsumoto TR; Zhao R; Galanter J; Lee C; Rae J; Toth B; Ramamoorthi N; Hackney JA; Berman A; Damjanov N; Fedkov D; Jeka S; Chinn LW; Townsend MJ; Morimoto AM; Genovese MC
Arthritis Rheumatol; 2020 Apr; 72(9):1435-46. PubMed ID: 32270926
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tripterygium wilfordii Hook F plus TNF inhibitor for active rheumatoid arthritis: A multicentre, randomized, double-blind, triple-dummy controlled trial.
Zhang X; Yang H; Zuo X; Wu L; Peng J; Li Z; Li H; Ji W; Zhang L; Li X; Dai L; Lu L; Yang N; Wei W; Shuai Z; Jiang Y; Liu Y; Lipsky PE; Chen H;
Clin Immunol; 2023 Oct; 255():109749. PubMed ID: 37657525
[TBL] [Abstract][Full Text] [Related]
4. Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer.
Gupta J; Nebreda AR
FEBS J; 2015 May; 282(10):1841-57. PubMed ID: 25728574
[TBL] [Abstract][Full Text] [Related]
5. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.
Goldstein DM; Kuglstatter A; Lou Y; Soth MJ
J Med Chem; 2010 Mar; 53(6):2345-53. PubMed ID: 19950901
[No Abstract] [Full Text] [Related]
6. Advances in kinase inhibition: treating rheumatic diseases and beyond.
Gadina M
Curr Opin Rheumatol; 2014 Mar; 26(2):237-43. PubMed ID: 24419749
[TBL] [Abstract][Full Text] [Related]
7. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
Lee JC; Laydon JT; McDonnell PC; Gallagher TF; Kumar S; Green D; McNulty D; Blumenthal MJ; Heys JR; Landvatter SW; Strickler JE; McLaughlin MM; Siemens IR; Fisher SM; Livi GP; White JR; Adams JL; Young PR
Nature; 1994 Dec 22-29; 372(6508):739-46. PubMed ID: 7997261
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.
Fisk M; Gajendragadkar PR; Mäki-Petäjä KM; Wilkinson IB; Cheriyan J
Am J Cardiovasc Drugs; 2014 Jun; 14(3):155-65. PubMed ID: 24504769
[TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6.
Guma M; Hammaker D; Topolewski K; Corr M; Boyle DL; Karin M; Firestein GS
Arthritis Rheum; 2012 Sep; 64(9):2887-95. PubMed ID: 22488549
[TBL] [Abstract][Full Text] [Related]
10. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
Yong HY; Koh MS; Moon A
Expert Opin Investig Drugs; 2009 Dec; 18(12):1893-905. PubMed ID: 19852565
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinases in innate immunity.
Arthur JS; Ley SC
Nat Rev Immunol; 2013 Sep; 13(9):679-92. PubMed ID: 23954936
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.
MacNee W; Allan RJ; Jones I; De Salvo MC; Tan LF
Thorax; 2013 Aug; 68(8):738-45. PubMed ID: 23539534
[TBL] [Abstract][Full Text] [Related]
13. "Go upstream, young man": lessons learned from the p38 saga.
Hammaker D; Firestein GS
Ann Rheum Dis; 2010 Jan; 69 Suppl 1(Suppl 1):i77-82. PubMed ID: 19995751
[TBL] [Abstract][Full Text] [Related]
14. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.
Tate CM; Blosser W; Wyss L; Evans G; Xue Q; Pan Y; Stancato L
J Biol Chem; 2013 Mar; 288(9):6743-53. PubMed ID: 23335506
[TBL] [Abstract][Full Text] [Related]
15. Roles of p38 MAPKs in invasion and metastasis.
del Barco Barrantes I; Nebreda AR
Biochem Soc Trans; 2012 Feb; 40(1):79-84. PubMed ID: 22260669
[TBL] [Abstract][Full Text] [Related]
16. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases.
Yasuda S; Sugiura H; Tanaka H; Takigami S; Yamagata K
Cent Nerv Syst Agents Med Chem; 2011 Mar; 11(1):45-59. PubMed ID: 20812905
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models.
Krementsov DN; Thornton TM; Teuscher C; Rincon M
Mol Cell Biol; 2013 Oct; 33(19):3728-34. PubMed ID: 23897428
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo?
Page TH; Brown A; Timms EM; Foxwell BM; Ray KP
Arthritis Rheum; 2010 Nov; 62(11):3221-31. PubMed ID: 20589681
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study.
Roman-Blas JA; Castañeda S; Cutolo M; Herrero-Beaumont G
Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1588-93. PubMed ID: 20556817
[TBL] [Abstract][Full Text] [Related]
20. The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese.
Clark AR; Dean JL; Saklatvala J
Arthritis Rheum; 2009 Nov; 60(11):3513-4. PubMed ID: 19877029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
